ATAGI 2023 booster guidance | Australian Federal government Section of Health and Aged Treatment

Date published:

The target of the Australian COVID-19 vaccination application remains the avoidance of severe disease from COVID-19. ATAGI has evaluated this possibility in the context of significant populace concentrations of hybrid immunity (i.e., put together immunity from previous an infection and earlier vaccination), the proof regarding COVID-19 vaccine success, which include for new bivalent vaccines, and the transforming epidemiology of COVID-19 linked to newly emerged subvariants of Omicron.

These recommendations substitute preceding ATAGI COVID-19 vaccine booster suggestions.


  • ATAGI recommends a 2023 COVID-19 vaccine booster dose for adults in the pursuing teams, if their very last COVID-19 vaccine dose or confirmed an infection (whichever is the most modern) was 6 months in the past or for a longer time, and regardless of the selection of prior doses obtained: 
    • All older people aged 65 years and over
    • Adults aged 18-64 several years who have health-related comorbidities that boost their danger of critical COVID-19, or incapacity with substantial or complicated wellbeing needs.
  • ATAGI advises the pursuing teams ought to consider a 2023 booster dose if their last COVID-19 vaccine dose or confirmed an infection (whichever is the most the latest) was 6 months in the past or extended, and no matter of the selection of prior doses been given, centered on an unique hazard benefit evaluation with their immunisation supplier. 
    • All Grown ups aged 18-64 many years with out possibility elements for critical COVID-19
    • Small children and adolescents aged 5-17 yrs who have medical comorbidities that boost their hazard of significant COVID-19, or disability with major or complicated health and fitness wants.
  • ATAGI advises that a booster dose is not suggested at this time for youngsters and adolescents aged less than the age of 18 who do not have any threat components for severe COVID-19.
  • Regarding vaccine selection,
Back To Top